Trial Profile
A Multi-center, Randomized, Double-blind, Parallel, Two-group Phase III Clinical Study of the Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Qilu Pharmaceutical
- 10 Sep 2019 Primary endpoint has been met. (Objective response rate)
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 22 Aug 2018 Status changed from recruiting to completed.